Sobi Set to Purchase Arthrosi Therapeutics

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Dec 15 2025

0mins

Source: NASDAQ.COM

Acquisition Details: Swedish Orphan Biovitrum AB (SOBI) has agreed to acquire Arthrosi Therapeutics for up to $1.5 billion, which includes an upfront payment of $950 million and contingent payments of up to $550 million.
Strategic Importance: The acquisition aims to enhance Sobi's gout treatment portfolio by adding pozdeutinurad, an investigational drug for managing progressive and tophaceous gout, currently in Phase 3 clinical studies.
CEO's Statement: Sobi's CEO, Guido Oelkers, highlighted the potential of pozdeutinurad to become a preferred therapy for patients with unresolved gout symptoms, projecting significant growth for the company through the mid-2030s.
Future Collaboration: Arthrosi will continue its partnership with Viva Biotech for the supply of active pharmaceutical ingredients, indicating ongoing business cooperation post-acquisition.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.